Literature DB >> 15233548

Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

E Saggiorato1, S Aversa, D Deandreis, F Arecco, A Mussa, B Puligheddu, S Cappia, S Conticello, M Papotti, F Orlandi.   

Abstract

Preoperative follicular lesion characterisation represents an unsolved diagnostic problem in thyroid nodular disease. Although fine-needle aspiration biopsy is the most reliable preoperative diagnostic procedure, it shows inherent limitations in differentiating adenoma from follicular carcinoma and, sometimes, follicular variants of papillary carcinoma. Galectin-3 cytoplasmic neoexpression has been proposed as a peculiar feature of thyroid malignant cells, easily detectable in cytological and histological samples. The aim of this study was to re-evaluate the galectin-3 expression in a large sample of thyroid lesions using an immunohistocytochemical biotin-free detection system and a specific anti-human-galectin-3 monoclonal antibody in order to avoid the interference of technical factors, a cause of conflicting results recently reported by some authors. We analysed galectin-3 expression of 39 follicular carcinomas, 26 papillary carcinomas, and 105 adenomas in both cell-block samples and their histological counterparts. All cell-block and histological papillary carcinoma samples showed high levels of galectin-3 immunoreactivity. Thirty-four follicular carcinomas were positive, whereas 5 were negative in cell-blocks but positive in their histological counterparts. Twelve out of 105 adenomas expressed galectin-3 in cell-blocks and histological samples. The diagnostic accuracy of preoperative galectin-3 evaluation in adenomas vs follicular carcinomas was 90.0%. Galectin-3 expression was also investigated in 22 minimally-invasive follicular carcinomas. All of them showed galectin-3 immunoreactivity in both cytological and histological specimens with the exception of two cases, where galectin-3 positivity was observed only in the surgical material. The routine correct use of galectin-3, by increasing the diagnostic accuracy of conventional cytology, improves the management of thyroid nodules and can lead to a sensitive reduction of useless thyroid surgeries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233548     DOI: 10.1007/BF03351054

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  46 in total

1.  Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules.

Authors:  Armando Bartolazzi; Mauro Papotti; Fabio Orlandi
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

Review 2.  Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis.

Authors:  A Raz; R Lotan
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

Authors:  A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

4.  Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.

Authors:  Miaw-Jene Liou; Err-Cheng Chan; Jen-Der Lin; Feng-Hsuan Liu; Tzu-Chieh Chao
Journal:  Cancer Lett       Date:  2003-03-10       Impact factor: 8.679

5.  Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.

Authors:  P L Fernández; M J Merino; M Gómez; E Campo; T Medina; V Castronovo; X Sanjuán; A Cardesa; F T Liu; M E Sobel
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

6.  The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds.

Authors:  J F Hamming; B M Goslings; G J van Steenis; H van Ravenswaay Claasen; J Hermans; C J van de Velde
Journal:  Arch Intern Med       Date:  1990-01

7.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.

Authors:  Luciane Martins; Sílvia E Matsuo; Kátia N Ebina; Marco Aurélio V Kulcsar; Celso U M Friguglietti; Edna T Kimura
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

8.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

9.  Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases.

Authors:  N P Caraway; N Sneige; N A Samaan
Journal:  Diagn Cytopathol       Date:  1993       Impact factor: 1.582

10.  Identification of galectin-3 as a factor in pre-mRNA splicing.

Authors:  S F Dagher; J L Wang; R J Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more
  14 in total

1.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

2.  Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.

Authors:  E Lippert; M Gunckel; J Brenmoehl; F Bataille; W Falk; J Scholmerich; F Obermeier; G Rogler
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

3.  Improving the prediction of malignancy in cytologically suspicious thyroid nodules.

Authors:  S Arena; A Latina; I Marturano; V Muscia; G L La Rosa; M Stornello; S Squatrito; S Italia; R Vigneri
Journal:  J Endocrinol Invest       Date:  2013-05-06       Impact factor: 4.256

Review 4.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

5.  Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

Authors:  Husain A Saleh; Bo Jin; John Barnwell; Opada Alzohaili
Journal:  Diagn Pathol       Date:  2010-01-26       Impact factor: 2.644

6.  Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis.

Authors:  Connie G Chiu; Reina Yao; Simon K Chan; Scott S Strugnell; Samuel Bugis; Robert Irvine; Donald Anderson; Blair Walker; Steven J Jones; Sam M Wiseman
Journal:  Can J Surg       Date:  2012-06       Impact factor: 2.089

7.  Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.

Authors:  Bogdan Galusca; Jean Marc Dumollard; Sandrine Lassandre; Alain Niveleau; Jean Michel Prades; Bruno Estour; Michel Peoc'h
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

8.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

9.  Regulation of prostate cancer progression by galectin-3.

Authors:  Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 10.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.